Quick Answer
Raphael Pharmaceutical Inc. reported Net Income of -$1.28 million for fiscal year 2025.
Raphael Pharmaceutical Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$1.28M | +15.8% |
| 2024 | -$1.52M | -13.0% |
| 2023 | -$1.34M | +60.0% |
| 2022 | -$3.36M | -106.8% |
| 2021 | -$1.62M | -126.2% |
| 2020 | -$718.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$255.0K | +21.8% | +20.8% |
| June 30, 2025 | -$322.0K | -29.8% | +24.9% |
| March 31, 2025 | -$429.0K | +22.0% | -31.6% |
| September 30, 2024 | -$326.0K | +55.0% | -31.5% |
| June 30, 2024 | -$248.0K | +40.5% | +54.9% |
| March 31, 2024 | -$550.0K | -108.3% | +24.1% |
| September 30, 2023 | -$725.0K | +49.8% | -73.9% |
| June 30, 2023 | -$417.0K | +33.5% | -58.0% |
- Raphael Pharmaceutical Inc. showed an increase of +15.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Raphael Pharmaceutical Inc.’s net income has declined by 78.1% (from -$718.0 thousand to -$1.28 million).
- The most recent figure is from Raphael Pharmaceutical Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: